PROMOTING PROGRESS
From bench to bedside

The 2016 Annual Report of the Society for Neuro-Oncology
This Annual Report covers the SNO 2015 fiscal year, from July 1, 2015 through June 30, 2016.
Dear Members and Colleagues of SNO,

I thank you for the opportunity and privilege to provide you with a summary of SNO’s accomplishments over this past year. I would like to recognize the leadership of our Officers: Vice-President, Terri Armstrong, and our Treasurer, Gelareh Zadeh. I would also like to recognize the work of the members of our Executive Committee and our Board of Directors.

Under the leadership of our Scientific Co-Chairs, Drs. Tracy Batchelor and Manish Aghi, the 2016 meeting in Scottsdale this November promises to exceed our expectations. With a special focus on the new WHO Guidelines, the meeting will likely be our largest and most educationally significant to date. Due to the increasing number of submitted abstracts (over 1000 this year — a new record!) our scientific chairs elected not to accept a small number of abstracts, evidence that our meeting is becoming more selective in the content that is being presented. The program will also feature several invited speakers for the plenary sessions, notably Drs. David Louis and David Ellison who will discuss the significance of WHO 2016, and Drs. Joseph Costello and Bradley Bernstein who will discuss genetics and epigenetics of tumor evolution.

In addition to the regular Scientific Meeting program, we also have an exciting Education Day on Thursday, chaired by Drs. Manmeet Ahluwalia, Jaishri Blakeley, Kristina Hardy, and Keith Ligon. The program will be focused on Precision Medicine and the new WHO Classification with sessions dedicated to basic and clinical science as well as clinical and applied neuro-oncology. An exciting mock tumor board will also be trialed for the first time during this day.

As you will read later in this Annual Report, this year SNO also organized several successful stand-alone events. I would like to thank Drs. Khaild Shah and Xing Fan for their efforts to organize the Neuro Tumor Club at AACR in New Orleans, and to recognize Gelareh Zadeh for her leadership on the Meningioma Conference that was held in Toronto.

Over the last year, three new committees were established. SNO is increasingly being asked to review, recommend changes and/or endorse guidelines related to diagnosis and/or treatment of CNS tumors. A Guidelines Committee, chaired by Drs. Tracy Batchelor and Susan Chang, is charged with overseeing endorsement requests. SNO is also the voice of numerous groups of stakeholders, including doctors, allied health professionals, scientists, patients, and industry partners. A new Public Policy Committee, chaired by Drs. Jann Sarkaria and Terri Armstrong, has thus been formed to help guide SNO on public policy issues. Finally, our educational efforts and our challenge to properly train the next generation of CNS oncologists have prompted the formation of a new Fellowship Matching Committee, chaired by Drs. John de Groot and Scott Plotkin, which is charged with helping to regulate the process of neuro-oncology fellowship matching.

This past January, SNO leadership met over two days at a strategic planning retreat to discuss the growth of our Society. With now over 2000 members, it is not unconceivable that SNO will grow to a size that requires larger venues for our Annual Meeting. Corresponding investments in new technologies to deliver educational content will also be needed. We continue to work to ensure that SNO retains the closeness and the nimbleness that has characterized its early years, while growing into a mature organization with the relevance and significance represented by its swelling membership numbers.

We are now planning for our next strategy retreat to be held in Miami in January 2017. The focus of this session will center around SNO’s publishing efforts, including our journals and our electronic publications. Dr. Patrick Wen, editor-in-chief of Neuro-Oncology, continues to lead our flagship journal to increasing success as evidenced by the number of readers and its latest citation impact score of 7.371. Dr. Susan Chang has now successfully nurtured Neuro-Oncology Practice through its early years of life and we expect that this journal will be indexed and start receiving impact factor scores in the next few years.

Our Society remains in great financial shape. Our total operating revenue continues to hover around the 3MM dollar range and we continue to accrue positive changes in our net assets on an annual basis. The last audit of our financial position was very positive, and we continue to remain vigilant for opportunities to increase revenue and reduce expense.

Finally, please join me in thanking Chas Haynes and all the members of SNO’s administrative office who work to ensure that the Society remains successful and responsive to our members.

Respectfully yours,

E.A. (Nino) Chiocca, MD PhD
As you will read in the pages of the Annual Report, 2016 was an exceptional year for our Society. It is certainly true that a constant factor in SNO’s success has been the dedication of its volunteer leadership. We are indebted to our out-going president, David Reardon, who led our Society with great skill. During his tenure, Dr. Reardon worked tirelessly to increase opportunities for young investigators within SNO, to expand our relationships with our Asian and European society partners and presided over a period of unprecedented growth both in terms of attendance at our Annual Meeting and our overall membership.

Our new president, Nino Chiocca, takes the reins of a Society that has never been financially stronger or in a better position to achieve its mission. Today we are in the enviable position of being able to make strategic investments back into the field of neuro-oncology. Guided by a long-range plan that we revisit each year, these investments are part of an on-going effort to introduce new technologies that will enhance the on-site experience for attendees at our Annual Meeting and deliver educational content in new and creative ways. This year we have enhanced our on-site meeting app, improved our e-poster delivery platform, added a presentation management system for oral presenters, and will introduce a new ways for attendees to interact with session moderators. As in year’s past, the Society remains extremely grateful to Erik Sulman for his leadership as chair of the SNO Technology Committee.

In addition to the Annual Meeting, SNO also participated in a number of topic-specific conferences. Led by Gelareh Zadeh, the Conference on Meningioma in Toronto was a great success. We continue to support educational opportunities like the SNO/SCIDOT Conference on Drug Delivery to the CNS, organized by Michael Vogelbaum, and the CNS Anticancer Drug Discovery and Development Conference, organized by Victor Levin. And this year we were honored to work with the International Symposium on Pediatric Neuro-Oncology (ISPN0) on their conference in Liverpool, and we look forward to playing an even greater administrative role when ISPN0 comes to Denver in 2018.

Noted in greater detail further in this Annual Report, our two journals continue to flourish. Under the editorial direction of Patrick Wen, the Impact Factor our flagship publication, Neuro-Oncology, is at an all-time high. Its sister journal, Neuro-Oncology Practice, continues to grow thanks to the efforts of Susan Chang. Also this year, SNO joined with the European Association of Neuro-Oncology (EANO) to launch a World Federation of Neuro-Oncology Societies Magazine. Published by Oxford University Press, the WFNOS Magazine can be downloaded at no charge from directly from the EANO website. SNO thanks Nicholas Butowski for representing SNO as a member of the editorial leadership of this important new publication.

This year the Society was pleased to welcome Carolyn Loch to the Society’s staff as our Manager of Medical Education. In this new position, Carolyn serves as the main administrative point of contact to the leadership of SNO’s various scientific meetings. She also coordinates the abstract submission and CME components of SNO’s meetings, and participates in several SNO committees, including the new Guidelines Committee. Carolyn is a Certified Clinical Research Professional and comes to SNO with a strong oncology background, having previously served for eight years as an oncology research nurse in the Department of Neuro-Oncology at MD Anderson Cancer Center in Houston.

Carolyn joins a superb administrative team who are dedicated to meeting the needs of our diverse membership. Whether in-person, by telephone, or email, it is clearly evident that they routinely go “above and beyond” to meet the needs of our diverse membership.

It is indeed an exciting time for our Society. With a shared vision of success, our physician leadership and administrative staff are well positioned to grow our existing programs, establish new initiatives and increase educational opportunities to better serve our growing membership.

J. Charles Haynes, JD
Dear Society for Neuro-Oncology Members and Supporters,

On behalf of the SNO Foundation, I am pleased to share with you that our financial position is excellent and our Society remains well-positioned to meet the diverse needs of our growing membership.

The SNO Foundation is the fundraising arm of SNO, and partners with the Society to support and fund various educational initiatives to better assist the clinicians, basic scientists, nurses and other health care professionals whose focus is central nervous system tumors in children and adults.

This year the Foundation was honored to partner with the University of Toronto to launch the Greg Wilkins-Barrick SNO International Outreach Course. The inaugural course was held in Malaysia on January 9, 2016 and was a great success. Future courses are planned for Sri Lanka and Morocco.

The Foundation has also continued to make strategic investments in several key aspects of our Annual Meeting. These include improvements to our e-poster delivery systems and on-site internet capabilities, the launch of a new electronic presentation management system for speakers, and on-going improvements in our on-site meeting app.

In addition to strategic investments in new technology, the support of our corporate and non-profit partners, as well as the generosity of our members, allows the Foundation to sustain SNO's core functions. This includes financial support for:

- The editorial offices of our official journals, *Neuro-Oncology* and *Neuro-Oncology Practice*
- Research awards and new initiatives for Young Investigators
- Travel scholarships to the annual meeting
- International outreach efforts

We are grateful to the non-profit associations and corporate donors who support the Foundation at the highest level as members of our Partner’s Advisory Council. The Council has direct access to the SNO Board of Directors and Foundation Executive Board on a regular basis. The 2015–2016 members of the Council include Bristol-Myers Squibb, Celldex Therapeutics, Genentech, the National Brain Tumor Society, Novocure, and the Sontag Foundation. We are pleased to welcome AbbVie as the newest member of the Partner’s Advisory Council.

The SNO Foundation remains committed to supporting important new initiatives and we continue to look ahead for additional opportunities to realize our common goal of improving the care and outcomes of patients with brain tumors.

Very truly yours,

Mark R. Gilbert, MD (Foundation President)
Mitchel S. Berger, MD
Susan M. Chang, MD
Victor A. Levin, MD
THE ADVANCING THE FIELD OF NEURO-ONCOLOGY FOR OVER 20 YEARS

The 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology was held on November 19–22 in San Antonio, Texas. Marking SNO’s 20th anniversary, the meeting was a great success, with record attendance of over 2100 registrants from 46 different countries.

The Society congratulates the Scientific Meeting Chairs, Tracy Batchelor and Gelareh Zadeh, for creating an exciting and comprehensive program, which highlighted innovative basic, translational, and clinical research. The meeting provided a collaborative environment for the exchange of ideas among clinical and laboratory scientists involved in the research, diagnosis, treatment, and care of patients with central nervous system tumors. Special thanks are also given to the Education Day Chairs, Gavin P. Dunn, Michael Lim, Hideho Okada, Michael Scheurer, and Jeffrey Wefel. The meeting was preceded by two well-attended pre-conference sessions: the SNO/SCIOP “Drug Delivery to the CNS” organized by Michael Vogelbaum, and the “Neuro-Oncology Review Course” organized by Maciej Mrugala.

The 2015 Education Day was entitled “Immunology and Immunotherapy” with sessions focusing on immune system biology, psychoneuroimmunology, patient factors affecting cancer outcomes, immunotherapy, animal models and brain imaging, pediatric brain tumor survivorship, toxicities related to immunotherapy, and case discussions.

The main Scientific Meeting expanded on the traditional SNO meeting format, which included plenary talks, top-scoring abstracts, minisymposia, “meet-the-experts” sunrise sessions, and events for young investigators, by incorporating a greater number of sunrise and lunchtime educational sessions and a SNO meeting highlights session organized by the Scientific Meeting Chairs.

On Thursday evening, the 2015 SNO Meeting Welcome Reception was held at the Henry B. Gonzalez Convention Center along with a concurrent Young Investigator’s Career Development and Networking Session.

On Friday the Scientific Meeting began with sunrise sessions, which included focused expert discussions on Quality of Life, Tumor Microenvironment/ Heterogeneity, Brain Metastases, Clinical Guidelines, Genetic Predisposition in Pediatric Brain Tumors, and Neurofibromatosis Type I. After an official welcome by Drs. Batchelor and Zadeh, the first plenary session kicked off with a minisymposium on precision medicine followed by the top-scoring abstracts. After a diverse set of lunch sessions, concurrent sessions were held on Clinical Trials, Tumor Biology, and Brain Metastases. In the evening, a symposium on Immunology and Oncology was followed by a poster session.

On Saturday, sunrise sessions covered the following topics: Vaccine Therapy, Low Grade Gliomas, Glioma Stem Cells, Lymphoma, and Glioma Molecular Epidemiology. The plenary session featured a minisymposium on Immunotherapy and was dedicated to the memory of neurosurgeon-scientist Dr. Andrew Parsa. The Victor Levin Award was presented to Dr. Mitchel Berger. Dr. David Reardon then delivered his Presidential Address, which included presentations of the Lifetime Achievement Award to Dr. W.K. Alfred Yung and the Public Service Award to Jan Esenwein. After lunch sessions, the afternoon rolled out with concurrent sessions on Tumor Biology, Pediatric Tumors, Neuroimaging, Surgical Therapeutics and Drug Delivery, an update on RANO criteria for clinical endpoints, and Rapid Reports. The evening began with a poster session and ended with the SNO Gala Dinner at the Knibbe Ranch, which provided SNO members with an opportunity to socialize while viewing armadillo races and enjoying some Texas hospitality.

Sunday’s sunrise sessions showcased expert panel discussions on Molecular Pathology, Circulating Biomarkers, Surgical Delivery of Therapeutics, Cell Signaling-Based Therapies, Neuroimaging, and the Genome and Epigenome of CNS Germ Cell Tumors. Afterwards, concurrent sessions were held on Molecular Pathology, Quality of Life/Neurocognition, Tumor Biology, and other topics through Rapid Reports. The meeting ended with remarks by the Scientific Meeting Chairs and presentation of awards for best discussed posters.

SNO thanks the Awards Committee for their efforts to select the 2015 award winners. Chair: David Eisenstat. Committee Members: Melissa Bondy, Eric Bouffet, Sidney Croul, John Darling, Spencer Gibson, Cynthia Hawkins, Craig Horbinski, Normand Laperriere, Joseph Megyesi, Ingo Mellinghoff, Janusz Rak, Stephen Sands, Erik Sulman, Martin Taphoorn, Martin van den Bent, Magimairajan Issai Vanan, Kyle Walsh and Stephen Yip.
SNO 20th Annual Meeting Abstract Award Winners

**ADULT CLINICAL RESEARCH**

Supported by the Sontag Foundation

Martin van den Bent

Final analysis of the BELOB trial (A randomized phase II study on bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma) and first radiology review results.

**CLINICAL RESEARCH – ADULT**

David Reardon, Co-Award Winner

ReACT: Long-term survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma

Susan Chang, Co-Award Winner

Results of NRG Oncology/RTOG 9813 - a phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA)

**BASIC RESEARCH – ADULT**

Andrew Venteicher, Co-Award Winner

Large-scale single-cell RNA-seq reveals a developmental cellular hierarchy in human oligodendroglioma

Felix Nwajei, Co-Award Winner

Refuting brain immune privilege: longitudinal multiphoton imaging through skull windows reveals the immune surveillance of brain metastases and its regulation by fractalkine

**TRANSLATIONAL RESEARCH – ADULT**

Anna Lasorella

Therapeutic vulnerabilities and resistance mechanisms for the precision medicine of glioblastoma

**TRANSLATIONAL RESEARCH – PEDIATRIC**

Nadia V Batora

BCOR is a novel tumor suppressor gene in SHH-driven medulloblastoma

**QUALITY OF LIFE RESEARCH – ADULT**

Jaqueline Stone

The impact of pregnancy on glioma patients

**Epidemiology Research – Adult**

Michael E Scheurer

Germline polymorphisms in MGMT increase ability to model temozolomide (TMZ)-related myelotoxicity risk in patients with glioblastoma (GBM) treated on NRG Oncology/RTOG 0825.

**YOUNG INVESTIGATOR – CLINICAL RESEARCH**

Kyle Walsh

ATRX and TERT assays provide non-redundant information in adult glioma patients: incorporating telomere markers into neuropathology practice

**ANDREW PARSA YOUNG INVESTIGATOR AWARD FOR BASIC/TRANSLATIONAL RESEARCH**

Deliang Guo

Lipid metabolism reprogramming in glioblastoma and serving as a promising target

The Victor Levin Lecture was delivered by Mitchel Berger (R), entitled Team Neuro-Oncology: The Sum is More Important than its Parts. Pictured here with Victor Levin (L).

WK Alfred Yung (L) received the 2015 SNO Lifetime Achievement Award for his contributions to the field of neuro-oncology, presented by SNO President David Reardon (R).

Jan Esenwein (L) received the SNO Public Service Award for her many years of service to the Society, presented by SNO Executive Director, Chas Haynes (R).
The Society is delighted to report continued success for its flagship journal, *Neuro-Oncology*. More submissions than ever have been processed — with a 15% increase over the previous year; if the trend continues until the end of 2016, the Journal estimates close to 850 new submissions this year. In spite of this increased workload, *Neuro-Oncology* still achieves fast peer-review of manuscripts with a mean time to first decision of about 30 days for the first 9 months of 2016.

**Impressive quality**

*Neuro-Oncology’s* focus on quality is reflected once again in its record high Impact Factor of 7.371 for 2015, ranking the Journal at 9 of 193 in Clinical Neurology and 19 of 213 Oncology titles. This is an achievement of which the editorial team can be proud.

**Impressive readership**

SNO’s, EANO’s, JSNO’s and SNOLA’s members, plus the global institutional distribution of the journal leads to almost 60,000 full-text or PDF downloads per month from the Journal.

During 2016 the journal started to publish article-level metrics for each paper published. Altmetric scores are a measure of the amount of attention an article has received online, in social media and from news sites — thus it is more a measure of the wider impact of a journal article. Hua Lin’s 2016 article on *Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells* (doi: 10.1093/neuonc/now128) achieved the highest Altmetric score this year to date: 606.

In conclusion, 2016 has been a great year for *Neuro-Oncology*, but 2017 will be even more exciting: the journal will launch a new internal design and new cover, as well as a much improved online presence on Oxford University Press’s new Academic Platform.
Neuro-Oncology Practice is now in its 3rd successful volume since launching in 2014. Under the expert and enthusiastic editorship of Dr. Susan Chang, Director of the Division of Neuro-Oncology at UCSF, the journal continues to carve its niche to provide the multidisciplinary field of all neuro-oncology professionals with accurate clinical information to enhance patient care.

Neuro-Oncology Practice is a truly international journal with authors from the world over — albeit with a large US contingent — reflecting the proportion of US-based research in this area.

Three years is not a long period for this journal to have increased readership and usage to the levels already now achieved. Neuro-Oncology Practice is currently a much smaller journal than Neuro-Oncology; as of October 2016 it had published 123 articles. It should be noted that this is according to plan. When establishing a new journal, starting small is the right approach to ensure high quality right from the start.

New for 2016 for Neuro-Oncology Practice is the establishment of a formal relationship with EANO; the journal has become an official publication of EANO and is now co-owned between EANO, SNO and OUP. All parties are delighted with this new arrangement, and see it as a key signal of European support going forwards.

Similar to Neuro-Oncology, 2017 will be an exciting year for the Journal with a new internal design and new cover as well as a much-improved online presence on Oxford University Press's new Academic Platform.
In addition to the Annual Meeting, SNO organizes stand-alone boutique meetings and works with sister societies on a range of educational initiatives. The highlights of these efforts, covering the fiscal year from July 1, 2015, to June 30, 2016, are provided below.

2016 Conference on Meningioma
The Conference on Meningioma was held in Toronto, Canada, in June. This highly successful meeting was organized by the Consortium on Meningioma in Toronto, with support from the Society for Neuro-Oncology. The Scientific Planning Committee included Gelareh Zadeh and Kenneth Aldape from the University of Toronto, Michael Vogelbaum from Cleveland Clinic and Ghazaleh Tabatabai from the University of Tübingen. This prestigious team organized a very scientifically robust and well-received meeting.

Chaired by Gelareh Zadeh, this two-day educational event brought together a focused multidisciplinary group of researchers and clinician scientists committed to improving the outcome of patients with meningioma through the translation of research into clinical practice. Over 100 high quality abstracts were submitted and contributed to the scientific excellence of the program. A mix of oral and poster presentations, as well as invited talks by internationally recognized and world class speakers, provided a great overview of advances in the diagnosis and treatment of meningioma. The first meeting of the International Meningioma Consortium was held at this conference, bringing together 11 international institutions with the aim to create a clinical, tissue and genomic repository for molecular analysis of aggressive meningiomas. In addition, a special Patient Advocacy session brought awareness to important issues facing patients and caregivers and included presentations by patients experiencing this disease as well as patient advocates from the American Brain Tumor Association, the Brain Tumour Foundation of Canada and the International Brain Tumour Alliance.

Based on very positive feedback from the attendees and survey results, this meeting received an excellent response with recommendations to support annual/biannual meningioma conferences. SNO and University of Toronto have a commitment to continue offering this scientific gathering to promote meningioma research, clinical management and advances in the field.

2016 Annual Neuro-Tumor Club Dinner Meeting
The 2016 Neuro-Tumor Club Dinner Meeting took place in New Orleans, Louisiana. This meeting, which has been organized every year by the Society for Neuro-Oncology for over two decades, has been a long-standing venue for brain tumor researchers attending the annual meeting of the AACR. The meeting took place at the Sheraton Hotel, which provided an excellent location in central New Orleans near the main AACR venue. SNO thanks co-chairs Khalid Shah and Xing Fan for organizing a lively and educational program.

Thirty-three abstracts of uniformly high quality were received, from which the Chairs ultimately selected 16 abstracts for presentation in four thematic sessions: Cancer stem cells and tumor heterogeneity; Tumor epigenetics and CNS metastases; Cell signaling in tumorigenesis and therapeutics; and Novel therapeutics and translational approaches. Sadly, it is SNO’s understanding that due to changes in the educational format of the AACR conference, third-party satellite meetings will not be permitted during future AACR events. Given the long-standing success of the Neuro-Tumor Club, the SNO leadership will explore new ways and formats to deliver important basic and translational neuro-oncology education to its membership. SNO thanks Drs. Shah and Fan for concluding the Neuro-Tumor Club — at least in its current format — with a tremendously successful evening in New Orleans.
Inaugural Wilkins-Barrick International Outreach Course

The Centre for Neuroscience Services & Research at the Universiti Sains Malaysia was given the honor of hosting the inaugural Wilkins-Barrick International Outreach Course in January of this year. This event was the result of an initiative led by Gelareh Zadeh, Co-chair of the SNO International Outreach Committee with the support of Mark Bernstein, the Greg Wilkins-Barrick Chair at the University Health Network, University of Toronto. Matching funds for the support of this course were provided by the SNO Foundation chaired by Mark Gilbert. The course was a great success, with 110 participants encompassing neurosurgeons, oncologists, radiologists and residents from across the country.

Led by Gelareh Zadeh and Jason Huse, the SNO International Outreach Committee is pleased to announce that two Wilkins-Barrick International Outreach Courses will be organized in 2017.

- Host: Neurosurgical Association of Sri Lanka
  Organizer: Ruvini Abeygunaratne
  Columbo, Sri Lanka
  January 21-22, 2017

- Host: Moroccan Society of Pediatric Hematology and Oncology
  Organizer: Laila Hessissen Marrakesh, Morocco
  April 5–7, 2017

SNO-SCIDOT Joint Conference on Therapeutic Delivery to the CNS

During the 2016 fiscal year, SNO was pleased to partner with the Society for CNS Interstitial Delivery of Therapeutics (SCIDOT) on a Joint Conference on Therapeutic Delivery to the CNS. This meeting, held immediately prior to SNO's Annual Meeting in San Antonio, addressed the multiple laboratory and clinical advances that are being made in the field of interstitial delivery of therapeutics. Michael Vogelbaum, representing SCIDOT, and Gelareh Zadeh, representing SNO, organized a very well-received two-day program that was attended by 235 registrants from around the world. Sessions covered a wide range of topics including the physiology of the blood-brain-barrier (BBB), methods for overcoming the BBB, development of novel technologies and techniques for surgical treatment of brain tumors, novel devices for delivering drugs directly into the brain, drug carriers, modeling of drug delivery, non-oncologic applications of direct delivery of therapeutics to the CNS, and provided attendees with updates on ongoing and completed clinical trials.

Neuro-Oncology Review Course

Chaired by Maciej Mrugala, the second Neuro-Oncology Review Course was held in San Antonino, Texas, on November 18. Attended by over 200 participants, this fast-paced activity provided high quality education and CME credits for those interested in reviewing and enhancing their knowledge in the principles of clinical neuro-oncology. This course, officially endorsed by the American Academy of Neurology, featured an expert faculty drawn from some of the top neuro-oncology programs in the US. In addition to a course syllabus, participants received take-away materials to help them prepare for specialty boards. A third consecutive Neuro-Oncology Review Course will be held prior to the 2016 SNO Annual Meeting in Scottsdale, Arizona.
The following financial highlights are prepared by management of Society for NeuroOncology for the fiscal year ended June 30, 2015 and are intended for this Annual Report, only. The audited financial statements of the organization are available upon request.

**Statement of Financial Position highlights, as of June 30, 2015**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$935,000</td>
</tr>
<tr>
<td>Investments</td>
<td>2,065,000</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>250,000</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>6,000</td>
</tr>
<tr>
<td>Endowment assets</td>
<td>229,000</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$3,485,000</strong></td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td><strong>$569,000</strong></td>
</tr>
<tr>
<td><strong>Net assets</strong></td>
<td><strong>2,916,000</strong></td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td><strong>$3,485,000</strong></td>
</tr>
</tbody>
</table>

**STATEMENT OF ACTIVITIES HIGHLIGHTS, FOR THE FISCAL YEAR ENDED JUNE 30, 2015**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues and other support</td>
<td>$2,871,000</td>
</tr>
<tr>
<td>Total program and supporting service expenses</td>
<td>2,481,000</td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td><strong>$390,000</strong></td>
</tr>
</tbody>
</table>
Society For Neuro-Oncology

Financial Highlights

Fiscal Year Ended June 30, 2016

The following financial highlights are prepared by management of Society for NeuroOncology for the fiscal year ended June 30, 2016 and are intended for this Annual Report, only. The financial information is in the process of being audited by an independent accounting firm. Once the audit is complete, the financial statements and Independent Auditor's Report will be posted at www.Soc-Neuro-Onc.org.

Statement of Financial Position highlights, as of June 30, 2016

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,285,000</td>
</tr>
<tr>
<td>Investments</td>
<td>2,251,000</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>299,000</td>
</tr>
<tr>
<td>Endowment assets</td>
<td>204,000</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$4,039,000</strong></td>
</tr>
<tr>
<td>Liabilities</td>
<td>$409,000</td>
</tr>
<tr>
<td>Net assets</td>
<td>3,630,000</td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td><strong>$4,039,000</strong></td>
</tr>
</tbody>
</table>

STATEMENT OF ACTIVITIES HIGHLIGHTS, FOR THE FISCAL YEAR ENDED JUNE 30, 2016

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues and other support</td>
<td>$3,517,000</td>
</tr>
<tr>
<td>Total program and supporting service expenses</td>
<td>2,803,000</td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td><strong>$714,000</strong></td>
</tr>
</tbody>
</table>
SNO STANDING COMMITTEES

The Audit Committee shall consist of the Chair, Vice President of the Society and the Secretary-Treasurer. The committee shall have the responsibility of overseeing annual internal audit of the Society’s financial affairs, and conveying the audit to the President and the Board, who may approve review of the audit by external committees as needed. The committee shall also advise and make recommendations to the Board of Directors based on findings of such audits. The Audit Committee members shall serve a two-year term and such term may be renewable at the discretion of the President. ● Chair: Gene Barnett

The Awards Committee shall consist of the Chair, the Scientific Program Chair and other members who shall develop criteria for all SNO meeting awards, annually review meeting award candidates, and forward to the Board a list of awards and award recipients to be honored at the Annual Meeting. The Awards Committee members shall serve a two-year term and such term may be renewable at the discretion of the President. ● Chair: Gelareh Zadeh

The Bylaws Committee shall consist of the Chair, the Secretary/Treasurer (ex officio) and two other members who shall review the Bylaws annually and make recommendations for revision as necessary. Members of this committee shall review any proposed changes and advise the Board of Directors on proposed revisions. The Bylaws Committee members shall serve a two-year term and such term may be renewable at the discretion of the President. ● Chair: David Schiff

The Communications Committee shall consist of the Chair, the Secretary/Treasurer (ex officio) and other members who shall be responsible for the news section of the Society’s official journal and the Society’s newsletter, and will have the responsibility of advising the Board of Directors on the Society’s internal and external communications. The Communications Committee members shall serve a two-year term and such term may be renewable at the discretion of the President. ● Chair: Albert Kim

The Fellowship Match Committee is responsible for developing and applying codes of conduct for fellowship programs, developing and applying codes of conduct for residents, developing match participation agreements, and other actions as necessary to ensure the operations of an effective fellowship matching program. The Fellowship Match Committee members shall serve a two-year term and such term may be renewable at the discretion of the President. ● Co-Chairs: John de Groot, Scott Plotkin

The Future Sites Committee shall consist of the Chair, a previous Chair of the Annual Meeting Committee and two other members who shall review potential sites and hotel proposals for future meetings, evaluating size and appropriateness of meeting space, availability and quality of sleeping rooms, proposed room rates, and recommends to the Board the most appropriate venue. The Future Sites Committee members shall serve a two-year term and such term may be renewable at the discretion of the President. ● Co-Chairs: Susan Chang, Mark Gilbert, James Perry

The Guidelines and Reported Outcomes Committee shall be responsible for the evaluation of internally and externally produced clinical practice guidelines of potential relevance to neuro-oncology practice and will be charged with recommending approval or revisions before consideration by the Board. ● Co-Chairs: Tracy Batchelor, Susan Chang
The International Outreach Committee shall consist of the Chair and other representative international members recommended by the Chair or President, as approved by the Board of Directors. The committee shall have the responsibility of advising and making recommendations to the Board of Directors on international affairs, promoting international membership, and shall develop the criteria and review candidates for SNO international outreach travel grants and fellowships. The International Outreach Committee members shall serve a two-year term and such term may be renewable at the discretion of the President. ● Co-Chairs: Jason Huse, Gelareh Zadeh

The Annual Meeting Committee shall consist of a Scientific Program Chair, Education Day Chair, the immediate past Chairs of the Annual Meeting Committee and other members representing each of the SNO specialty areas who shall supervise and coordinate all aspects of the next SNO Scientific Meeting and Education Day. The Meeting Committee members shall serve a one-year term and such term may be renewable at the discretion of the President. ● Scientific Meeting Co-Chairs: Tracy Batchelor, Manish Aghi. Education Day Co-Chairs: Manmeet Alhuwalia, Keith Ligon. Clinical & Applied Neuro-Oncology Co-Chairs: Kristina Hardy, Jaishri Blakeley

The Membership Committee shall consist of the Chair and four members who shall make recommendations to the Board of Directors concerning efforts to promote and increase membership in Society. They shall also review and vote on all applicants for membership and shall evaluate a member's professional conduct as requested by a majority of the Board of Directors. The Membership Committee members shall serve a two-year term and such term may be renewable at the discretion of the President. ● Chair: Gavin Dunn

The Public Policy Committee shall advise the Board of Directors on legislative, regulatory and advocacy issues that may impact or be of interest to the SNO membership. The committee will evaluate and recommend official position statements and act as a conduit for enquiries of a public policy nature from external constituencies. It will focus on public policy issues and may be approached with opportunities to provide input related to funding or ethical issues. ● Co-Chairs: Terri Armstrong, Jann Sarkaria

The Technology Committee shall consist of the Chair and other members who shall have the responsibility of coordinating and overseeing the Society's official website. The Technology Committee members shall serve a two-year term and such term may be renewable at the discretion of the President. ● Chair: Erik Sulman

The Young Investigators Committee shall consist of the Chair and other members who shall have the responsibility of advising the Board of Directors on issues pertaining to graduate students, residents, fellows and members within the first five years of their initial clinical or academic appointment. The Young Investigators Committee shall also have the responsibility of coordinating the SNO Grant Review initiative. The Young Investigators Committee members shall serve a two-year term and such term may be renewable at the discretion of the President. ● Chair: Monica Venere
Executive Director
J. Charles Haynes, JD

Chief Administrative Officer
Jan Esenwein

Manager of Medical Education
Carolyn Loch, RN

Manager, Member & Program Services
Linda Greer

Marketing and Exhibits Specialist
Megan Bell

Administrative Coordinator
Ginger Vazquez

Communications Coordinator
Kristin Odom

Bookkeeper
Martha Maloch

Society for Neuro-Oncology
PO Box 273296
Houston, TX 77277
tel 713.526.0269
fax 832.201.8129

www.soc-neuro-onc.org
SNO SUPPORTERS

Platinum
AbbVie
Bristol-Myers Squibb
Celldex Therapeutics
Genentech
National Brain Tumor Society
Novocure
The Sontag Foundation

Benefactor
CERN Foundation
SNO Foundation

Supporter
AbbVie
Medtronic

Contributor
American Brain Tumor Association
BrainLab
CERN Foundation
Elekta
Houston Methodist Neurological Institute
Medtronic
Northwest Biotherapeutics
Orbus Therapeutics
The EndBrainCancer Initiative
Tocagen

International Outreach
& Levin Society
Anonymous
Children’s Brain Tumor Foundation
Ali Choucair
Employees of Abbott Labs
Sontag Foundation
SNO Foundation
University of Toronto, Mark Bernstein
Victor and Ellen Levin
Victor Levin Founders Society

Neuro-Tumor Club Meeting
Celldex
Novocure

Exhibitors
AbbVie
Ambry Genetics
American Brain Tumor Association
Arbor Pharmaceuticals Hospital Team
Arbor Pharmaceuticals Medical Affairs
Brainlab
Bristol-Myers Squibb
Caris Life Sciences
Celldex Therapeutics
CERN Foundation
ContextMedia: Health
DFINE Inc.
Elekta
Elsevier Inc.
Foundation Medicine
Genentech
Houston Methodist Hospital - Peak Center
IMRIS
Infuseon Therapeutics
International Brain Tumour Association
IsoRay Medical
LabCorp
Li-Fraumeni Syndrome Association
MagForce AG
Mayo Clinic
Medtronic Inc.
Monteris Medical
National Brain Tumor Society (NBTS)
Nexstim
Nicki Leach Foundation
NICO Corporation
Northwest Biotherapeutics
Novartis
Novocure
Orbus Therapeutics, Inc.
Oxford University Press
Renishaw PLC
RiboMed Biotechnologies, Inc.
Sigma Tau
Sontag Foundation
Synaptive Medical
Terra Biological LLC
The EndBrainCancer Initiative
The Sontag Foundation
Tocagen
UCB Pharma, Inc.
University of Florida Health Neuromedicine
Vascular Biogenics Ltd. Therapeutics
Voices Against Brain Cancer
MISSION
SNO fosters multidisciplinary neuro-oncology research and education to improve patient outcomes.

VISION
SNO is the pre-eminent multidisciplinary society involved in state-of-the-art neuro-oncology research, education, and patient care.